Reviva Pharmaceuticals (RVPH) said Monday that preliminary topline data from a phase 3 study of brilaroxazine in patients with schizophrenia was positive as it demonstrated "robust broad-spectrum efficacy" that was sustained for more than one year.
The biopharmaceutical company also said brilaroxazine was generally well tolerated with no single side effect and favorable compliance.
Shares of Reviva Pharmaceuticals were up over 2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.